Decibel Therapeutics is translating recent scientific advances in understanding the factors that cause hearing loss into novel therapies for a broad range of people with hearing disorders. By combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, Decibel is pioneering a comprehensive approach to defining the underlying biological causes of hearing loss and developing a pipeline of breakthrough therapies targeted to specific patient populations.
Hearing loss is commonly mischaracterized as an issue only associated with aging, but continues to be a serious and growing concern for people of all ages. Explained below are significant hearing disorders, and symptoms of hearing loss such as tinnitus, that affect millions of people, but may be less familiar to the general public. Decibel Therapeutics’ goal is to be the leading company focused broadly across hearing disorders, including: children with cancer or cystic fibrosis who commonly experience ototoxicity, or hearing loss as a side effect of drug treatment; noise-induced hearing loss; residual hearing preservation or improved sound fidelity with cochlear implants; presbycusis, or age-related hearing loss; tinnitus, a symptom of underlying hearing conditions that manifests as a persistent ringing in the ears; and genetic hearing loss.
The underlying science of hearing has reached a tipping point, and we’re closer than ever to understanding the molecular basis of the pathogenesis and pathophysiology of hearing loss. Decibel has identified acute, targeted indications that that can provide near-term opportunities for human proof-of-concept for the company’s therapeutic candidates. These clinical studies will evaluate therapies for people with significant unmet needs, as well as provide the foundation for moving into larger, chronic hearing disorders. Decibel’s goal is to be the world leading hearing therapeutics company.